Greater Cannabis Company Inc (GCAN) is a cannabinoid therapeutics company focused on research and development of cannabinoid-based drug formulations. The company has no disclosed revenue-generating operations as of its 10-K filed March 31, 2026 (fiscal year ended December 31, 2024), and funds operations through external financing rather than product sales. GCAN competes in the cannabis therapeutics space against Jazz Pharmaceuticals (NASDAQ: JAZZ) and Zynerba Pharmaceuticals (NASDAQ: ZYNE), among others. The company is incorporated in Florida and maintains office space at 15 Walker Street, Suite 101, Baltimore, Maryland 21208, leased from CEO Aitan Zacharin at no cost. GCAN plans to allocate approximately $250,000 from financing proceeds toward R&D of new cannabinoid therapeutic formulations and intends to file patents protecting resulting intellectual property. Audit fees for fiscal year ended December 31, 2024 totaled approximately $7,100, consistent with a pre-revenue, early-stage company. Zacharin, who co-founded Fuse Science in 2012 and has experience in biopharmaceutical and consumer products businesses, serves as chief executive officer.

Revenue model

No product revenue disclosed in the 10-K filed March 31, 2026. The company funds operations through external financing, including convertible notes and warrant agreements with parties such as Emet Capital Partners.

Products and services

Cannabinoid-based therapeutics in research and development. The company is developing new formulations around cannabinoid therapeutics and plans to file patents on resulting intellectual property, per the 10-K filed March 31, 2026.

Customers and end markets

No customers or commercial end markets disclosed in the filing excerpts. Target end market is cannabinoid-based pharmaceuticals and therapeutics.

Value-chain role

Early-stage R&D company positioned upstream in the cannabinoid therapeutics value chain, focused on drug formulation development and intellectual property creation rather than manufacturing or distribution.

Geographic exposure

United States. Principal office in Baltimore, Maryland as of the 10-K filed March 31, 2026.

Competitors

Jazz Pharmaceuticals (NASDAQ: JAZZ), Zynerba Pharmaceuticals (NASDAQ: ZYNE)

Source: SEC 10-K, filed 2026-03-31

Industry: Pharmaceutical Preparations